Neuropeptide Research: Semax, Selank, and DSIP — Mechanisms and Applications

Neuropeptide Research: A Distinct Research Category

Neuropeptides are short peptides produced in the nervous system (and peripheral tissues) that act as signaling molecules in the CNS, neuroendocrine system, and immune-nervous system interface. Unlike classical neurotransmitters, neuropeptides are typically larger molecules released from secretory granules, act at G-protein-coupled receptors, and often have modulatory rather than excitatory/inhibitory primary roles.

Three neuropeptide research compounds occupy distinct positions in the published research literature: Semax, Selank, and DSIP. Each emerged from a different research tradition and acts through different primary mechanisms — making them complementary tools rather than alternatives in neuropeptide research designs.

Mechanism Comparison Matrix

Individual Compound Profiles

Semax — ACTH-Derived Neuroprotection and Cognitive Research

Semax is a synthetic heptapeptide derived from the 4–10 sequence of adrenocorticotropic hormone (ACTH), with a C-terminal Pro-Gly-Pro stabilizer sequence added to protect against exopeptidase degradation. The original ACTH(4–10) sequence (Met-Glu-His-Phe-Arg-Trp-Gly) retains the core melanocortin receptor-binding domain but lacks the ACTH N-terminal sequence responsible for adrenal cortex stimulation — meaning Semax does not stimulate cortisol secretion despite its ACTH origin.

• BDNF and NGF upregulation: Semax is among the most consistently characterized peptides for inducing BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the CNS, particularly in hippocampal and frontal cortical regions
• Ischemia and stroke models: Published studies have used Semax in rodent middle cerebral artery occlusion (MCAO) models and other cerebral ischemia designs, examining neuroprotective endpoints including infarct volume, neurological deficits, and inflammatory marker profiles
• Dopaminergic modulation: ACTH(4–7) (a sub-fragment) has been shown to interact with dopamine receptor signaling; Semax maintains this activity in published research examining dopaminergic pathway regulation
• VEGF-mediated neuroprotection: Semax administration in animal models has been associated with upregulation of vascular endothelial growth factor (VEGF) in neural tissue — a mechanism studied in the context of post-ischemic angiogenesis and neuroprotection

Semax is typically administered intranasally in published animal protocols, exploiting the olfactory pathway for CNS delivery. It has a short plasma half-life (~minutes) that limits systemic exposure while facilitating direct CNS access via the nasal route.

→ Semax research primer

Selank — Tuftsin-Derived Anxiolytic and Immunomodulatory Research

Selank is a synthetic stabilized analog of tuftsin — an endogenous tetrapeptide (Thr-Lys-Pro-Arg) found in the Fc region of IgG immunoglobulin. Native tuftsin is rapidly degraded by serum enzymes; Selank extends the core tuftsin sequence with a Pro-Gly-Pro tail, substantially improving plasma stability without altering the core pharmacophore.

• GABAergic modulation: Selank has been reported to potentiate GABA-A receptor activity in electrophysiological preparations, producing anxiolytic-profile behavioral effects in animal models without the sedation or dependence liability associated with benzodiazepine GABA-A modulators
• BDNF modulation: Like Semax, Selank increases BDNF expression in hippocampal and frontal cortical tissue in animal models — though the magnitude of effect is generally reported as smaller than with Semax, consistent with their different primary mechanisms
• Immunomodulatory effects: Tuftsin is the endogenous immune regulatory peptide from which Selank derives; published research has examined Selank's effects on phagocytic activity, cytokine profiles, and immune cell function — a research area where Semax has less literature
• Stress response models: Selank has been investigated in rodent anxiety and stress response paradigms, with anxiolytic-profile effects (reduced social avoidance, altered open-field exploration) without sedation

→ Selank research primer

DSIP — Sleep Architecture and HPA Axis Research

DSIP (delta sleep-inducing peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during slow-wave sleep. Its research profile has expanded considerably beyond its original sleep-inducing characterization:

• Sleep architecture: Published animal studies have characterized delta-wave EEG activity changes following DSIP administration — the basis for its original name. Modern research frames DSIP as a neuromodulator of the sleep-wake interface rather than a simple sleep inducer
• HPA axis modulation: DSIP has been studied in the context of ACTH and cortisol secretion regulation, CRH pathway interactions, and glucocorticoid receptor sensitivity — overlapping with the HPA axis research space where Semax also operates (through different primary mechanisms)
• Opioid tolerance models: DSIP administration has been studied in rodent opiate tolerance designs, with proposed mechanisms involving GABAergic and opioid receptor sensitization
• BBB permeability: DSIP is notable for apparent carrier-mediated BBB penetration intact — unusual for a peptide of its mass, and critical for its central neuromodulatory research utility following peripheral administration

→ DSIP research primer

Selecting the Right Neuropeptide Research Tool

Use Semax — the most consistently reproduced peptide for BDNF/NGF upregulation in the published neuropeptide literature.

Use Selank — its tuftsin-derived GABA-A potentiation provides an anxiolytic research model without typical BZD pharmacology confounders.

Both DSIP (direct HPA modulation via CRH/ACTH pathways) and Semax (ACTH-derived, though without adrenal cortex stimulation) have published HPA axis research contexts. DSIP is the primary tool for sleep-related HPA research; Semax for neuroprotective and ischemia-related HPA contexts.

DSIP (carrier-mediated BBB transport), Semax (intranasal/olfactory pathway), and Selank (reported BBB penetration) all represent different models of peripherally administered CNS-acting neuropeptides. The mechanism of CNS access differs for each, making them individually useful for studying neuropeptide delivery routes.

Shared Research Characteristics

All three neuropeptides share several properties relevant to laboratory research:

• Short half-life in plasma: All three are susceptible to serum proteases. Structural modifications (Pro-Gly-Pro stabilizer in Semax and Selank; tryptophan at position 1 in DSIP) provide partial protection but not long-term plasma stability
• CNS accessibility: All three have documented or proposed mechanisms for CNS access following peripheral administration, which distinguishes them from neuropeptides that cannot cross the BBB
• Non-addictive research profile: Published research on Semax and Selank specifically addresses the absence of dependence-associated behavioral markers in animal models — relevant for anxiety and cognitive research designs where this distinction matters
• Russian/Eastern European research tradition: All three have substantial primary published literature from Russian or Eastern European institutions, complemented by more recent publications in Western journals

Laboratory Handling Notes

All three are lyophilized peptides. Reconstitute in sterile water or bacteriostatic water. Store lyophilized at −20 °C; reconstituted at 2–8 °C. Semax is typically used via intranasal route in published animal protocols; Selank and DSIP via parenteral routes. See the reconstitution guide for standard protocol.

Yes — they are among the most commonly combined neuropeptides in published research, addressing complementary CNS mechanisms (BDNF/dopaminergic/neuroprotection for Semax; GABAergic/anxiolytic for Selank). The two compounds share BDNF upregulation as a secondary endpoint but through different primary mechanisms. Published combination studies have examined synergistic effects on anxiety and cognitive function models in rodents.

Semax and Selank primarily modulate neurotrophic factor expression and neurotransmitter receptor activity. DSIP's primary published characterization involves HPA axis modulation (ACTH/cortisol regulation, CRH pathway interactions) and sleep architecture (delta-wave EEG modulation) — a fundamentally different mechanistic profile despite all three being classified as neuropeptides. DSIP's opioid system interactions also distinguish it from Semax and Selank, which have less published research in the opioid receptor space.

See Also

• Lab Testing & Verified Purity — HPLC and LC-MS testing methodology for research peptides
• Peptide Storage & Stability — stability guidance for neuropeptide research stocks
• How to Reconstitute Research Peptides — laboratory reconstitution workflow
• Peptide Half-Life Reference — compiled pharmacokinetic data including Semax, Selank, and DSIP
• What Are Research Peptides? — foundational overview of peptide synthesis and research applications
• Kisspeptin: GnRH Signaling and HPG-Axis Research — KISS1R receptor biology, GnRH neuron signaling, and HPG-axis research context

Research Compound Availability

The compounds discussed in this overview are available for laboratory research. Browse lot-specific batch documentation for each:

• Semax
• Selank
• DSIP

All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.